Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.01. | Arcutis Biotherapeutics, Inc.: ZORYVE (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids | 317 | GlobeNewswire (Europe) | New subgroup analysis from STRATUM study shows that individuals with an inadequate response, contraindication, or intolerance to steroids were 3.5 times more likely to achieve IGA Success with ZORYVE... ► Artikel lesen | |
14.01. | Arcutis Biotherapeutics, Inc.: Majority of Individuals with Atopic Dermatitis Improved with Arcutis' Roflumilast Cream 0.15% According to New Data from Phase 3 Program | 340 | GlobeNewswire (Europe) | Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and Severity Index (EASI) in just 4 weeks85% achieved measurable... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
SUPER MICRO COMPUTER | 4.000 |
EVOTEC | 3.194 |
TUI | 2.816 |
NVIDIA | 2.764 |
BAYER | 2.667 |
NEL | 2.482 |
RENK GROUP | 1.792 |
RHEINMETALL | 1.713 |
TESLA | 1.308 |
PALANTIR TECHNOLOGIES | 1.291 |
VOLKSWAGEN | 1.271 |
DEUTSCHE BANK | 1.155 |
PLUG POWER | 1.079 |
AMAZON | 1.046 |
BYD | 1.046 |
MICROSTRATEGY | 1.046 |
PROSIEBENSAT.1 | 1.033 |
BASF | 1.025 |
COMMERZBANK | 1.023 |
MERCEDES-BENZ | 951 |
THYSSENKRUPP | 936 |
JINKOSOLAR | 893 |
ALLIANZ | 890 |
AIXTRON SE | 885 |
DEUTSCHE TELEKOM | 880 |